A placebo-controlled pilot study of intensification of antiretroviral therapy with mycophenolate mofetil

AIDS Research and Therapy

Volumn 3, Issue 1, 2006, Pages

  Kaur, Rupinderjeet ^a   Bedimo, Roger ^a,c   Kvanli, Mary Beth ^c   Turner, Diana ^c   Shaw, Leslie ^b   Margolis, David ^a,c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CELL SURFACE MARKER; DIDANOSINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; STAVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ABSENCE OF SIDE EFFECTS; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; NONHUMAN; OPEN STUDY; PATIENT COMPLIANCE; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REBOUND; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; VIREMIA; VIRUS INHIBITION; VIRUS LOAD;

EID: 33748641965     PISSN: 17426405     EISSN: None     Source Type: Journal    
DOI: 10.1186/1742-6405-3-16     Document Type: Article

References (19)

1. Allison AC, Eugui EM: Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev 1993, 136:5-28.
2. Ransom TJ: Mechanism of action of mycophenolate mofetil. Ther Drug Monit 1995, 17:681-684.
3. Ichimura H, Levy JA: Polymerase substrate depletion: a novel strategy for inhibiting the replication of the human immunodeficiency virus. Virology 1995, 211:554-560.
4. Margolis DM, Heredia A, Gaywee J, Oldach D, Drusano G, Redfield RR: Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity. J Acquir Immune Defic Syndr 1999, 21:362-70.
5. Heredia A, Margolis D, Oldach D, Hazen R, Le N, Redfield R: Abacavir in combination with the inosine monophosphate dehydrogenase (IMPDH)-inhibitor mycophenolic acid is active against multidrug- resistant HIV-1. J Acquir Immune Defic Syndr 1999, 22:406-407.
6. Hossain MM, Coull JJ, Drusano GL, Margolis DM: Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir. Antiviral Res 2002, 55(1):41-52.
7. Coull JJ, Turner D, Betts M, Melby T, Lanier ER, Margolis DM: A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1. J Acquir Immune Defic Syndr 2001, 26:423-434.
8. Margolis DM, Kewn S, Coull JJ, Ylisastigui Y, Turner D, Wise H, Hossain MM, Lanier ER, Shaw LM, Back DJ: The Addition of Mycophenolate Mofetil to Antiretroviral Therapy Including Abacavir is Associated with Depletion of Intracellular Deoxyguanosine Triphosphate and a Decrease in Plasma HIV-1 RNA. J Acquir Immune Defic Syndr 2002, 31:45-49.
9. Garcia F, Plana M, Arnedo M, Brunet M, Castro P, Gil C, Vidal E, Millan O, Lopez A, Martorell J, Fumero E, Miro JM, Alcami J, Pumarola T, Gallart T, Gatell JM: Effect of Mycophenolate Mofetil on Immune Response and Plasma and Lymphatic Tissue Viral Load During and After Interruption of Highly Active Antiretroviral Therapy for Patients with Chronic HIV Infection: A Randomized Pilot Study. J Acquir Immune Defic Syndr 2004, 36(3):823-830.
10. Chapuis AG, Paolo Rizzardi G, D'Agostino C, Attinger A, Knabenhans C, Fleury S, Acha-Orbea H, Pantaleo G: Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. Nat Med 2000, 6(7):762-788.
11. Sankatsing SU, Hoggard PG, Huitema AD, Sparidans RW, Kewn S, Crommentuyn KM, Lange JM, Beijnen JH, Back DJ, Prins JM: Effect of mycophenolate mofetil on the pharmacokinetics of antiretroviral drugs and on intracellular nucleoside triphosphate pools. Clin Pharmacokinet 2004, 43(12):823-832.
12. Kaur R, Klichko V, Margolis D: Ex vivo modeling of the effects of mycophenolic acid on HIV infection: considerations for antiviral therapy. AIDS Res Hum Retroviruses 2005, 21(2):116-124.
13. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, Hellmann NS, Petropoulos CJ, McCune JM, Hellerstein MK, Grant RM: Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001, 344(7):472-480.
14. Back NK, Nijhuis M, Keulen W, Boucher CA, Oude Essink BO, van Kuilenburg AB, van Gennip AH, Berkhout B: Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J 1996, 15(15):4040-4049.
15. Tenorio AR, Smith KY, Kuritzkes DR, Sha BE, Donoval B, Young R, Jennings C, Bremer J, Shott S, Landay A, Kessler HA: HIV-1-infected antiretroviral-treated patients with prolonged partial viral suppression: clinical, virologic, and immunologic course. J Acquir Immune Defic Syndr 2003, 34(5):491-496.
16. Piketty C, Weiss L, Thomas F, Mohamed AS, Belec L, Kazatchkine MD: Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen. J Infect Dis 2001, 183(9):1328-1335.
17. Press N, Kimel G, Harris M, Yip B, Craib KJ, Montaner JS: Case series assessing the safety of mycophenolate as part of multidrug rescue treatment regimens. HIV Clin Trials 2002, 3(1):17-20.
18. Sankatsing SU, Jurriaans S, van Swieten P, van Leth F, Cornelissen M, Miedema F, Lange JM, Schuitemaker H, Prins JM: Highly active antiretroviral therapy with or without mycophenolate mofetil in treatment-naive HIV-1 patients. AIDS 2004, 18(14):1925-1931.
19. Fumero E, Garcia F, Gatell JM: Immunosuppressive drugs as an adjuvant to HIV treatment. J Antimicrob Chemother 2004, 53(3):415-417.